Author: Bruce Carlson
The announcement that Franklin Lakes, NJ-based Becton Dickinson is going to spin off its diagnostics (and life sci) unit and concentrate on medical technology made news this week. While we didn’t prognosticate it, it’s not surprising. Becton Dickinson (BD) is into a lot. It’s huge in specimen handling, both in volume and innovation. It’s a leader in microbiology, which let’s face it, could be a whole company in and of itself, given the needs there. It offers advanced patient management systems, and flow cytometry. And that’s only part of it. Now, It’s chosen to form a “New BD” that will…
Sign up now, there’s only 100 slots for this webinar. JOIN HERE FOR ZOOM WEBINAR: https://us06web.zoom.us/webinar/register/WN_RpmYgJtFS_qbg5HZNEZfEg
OK, we are paraphrasing here. But if you look at the recent approvals, you see in vitro diagnostic test makers saying it, adopting an approach of let’s test for what can best help providers. Don’t get their intentions wrong, they plan to sell the big comprehensive tests too. But what they are pushing is testing for the important. Case in point: Inflammatix, more or less is saying “We got to stop thinking about sepsis as a disease.” We have to stop ruling it “in,” or ruling it “out.” Now I am paraphrasing, but this is the war-weary cry of many…
Developments in artificial intelligence and in vitro diagnostics including: regulations, new products, and expert viewpoints are constant. Here we list some notable links in AI and IVD we are tracking. TEMPUS AI WILL BUY AMBRY: Tempus AI has announced an agreement to acquire Ambry Genetics for $375 million in cash and $225 million in shares. Ambry is Tempus’ primary reference lab. The deal will combine Ambry’s extensive genetic testing capabilities with its AI-driven data analytics platform. [READ MORE] https://www.cooley.com/news/coverage/2024/2024-11-04-tempus-announces-$600-million-acquisition-of-ambry-genetics ROCHE BETS ON AI-DRIVEN PATHOLOGY: Roche announced it had integrated over 20 AI algorithms from eight collaborators into its digital pathology…
It would be a stretch to say the J.P. Morgan Healthcare Conference is an in vitro diagnostics meeting. Healthcare IT and pharmaceutical deals traditionally dominate the handshakes there, and that’s no exception this year. Heck, one pharma deal announced at JPM would equal a seventh of the entire IVD market, just one deal. But we aren’t bitter. In fact, IVD is always represented at JPM, and investors have always been interested; particularly in companion packages and novel tech. So far, a few nuggets are worth reporting that might be of interest to IVD watchers: Roche Sees Mid to High Single-Digit…
Lab-developed tests, lab consolidation and infectious disease threats dominated the news relative to in vitro diagnostic (IVD) companies in 2024, Eye On IVD notes. Other stories, such as rising fungal infections and studies have not been as but are just as important. These stories have been covered by our Linked In newsletter and our email (subscribe at eye on IVD.com). Eye On IVD notes the following stories: TOP STORY: FDA Lab-Developed Test Policy It should be no surprise that the top story of 2024 in the laboratory industry, spilling over into the IVD supplier industry, is the FDA’s change in…
A TALE OF 137 TERABYTES: WEBINAR TALKS ABOUT DATA OPPORTUNITY IN IVD THANKS TO WEARABLES AND AI Imagine 60 laptops. Now imagine that’s how much data is being generated every day by clinical providers. This was the point emphasized by Frank Criscione of Broadbranch Advisors (www.broadbranchadvisors.com) during the EYE ON IVD “Very Cutting-Edge Trends in IVD Webinar. In 2023, he said, clinical diagnostic providers globally generated an estimated *137 terabytes of data daily. This massive volume highlights the growing data generation trend driven by an aging population, increasingly sophisticated diagnostic tests, and emerging technologies. The video of the VERY CUTTING-EDGE…
Among the many predictions made in our latest webinar, “Very Cutting-Edge Trends in IVD” was that we can expect a “lab-in-a-box” type system to receive FDA approval within the next 2 years. We’ll explain why here. But first – we wanted to highlight our EYE ON IVD End of The Year Sale on All of Our Market Research, w/Discounts up to 20%. Visit our Research Shop Now for details: https://eyeonivd.com/research-report-shop/ Lab-in-a-box systems, ranging in size from a printer to a refrigerator, were once the stuff of talk, but have since made progress in development. This according to Eye on IVD’s…
On December 4th, Eye On IVD consulted three IVD industry experts to talk about less than notable trends. We have received many requests for our webinar for those who were not able to make the live presentation or would like to re-hear it. Please find below our Very Cutting-Edge Trends IVD Webinar in video and transcript format: Webinar Participants: Rob Lacroix, LTC LLC Frank Criscione, Broadbranch Advisors David Freestone, BridgeworX Bruce Carlson, Eye On IVD A transcript is available below. We note that it is an AI-generated sound transcript of the webinar, and thus there may be some imperfections; best…
According to Siemens, nearly 49% of patients with elevated troponin I levels may experience a major adverse cardiac event or death within the year. For this reason, Siemens Healthineers has been highlighting the FDA clearance of a new prognostic indication for its Atellica IM high-sensitivity troponin I (TnIH) test. The blood test helps healthcare providers identify patients at risk of death or major cardiac events within one year after presenting to the emergency department (ED) with acute coronary syndrome symptoms. Cardiac troponin I is a biomarker for heart muscle injury. Siemens in a press release featured the use of the…